Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved..
Patients with hepatitis C virus (HCV) genotype 4 infection are poorly represented in clinical trials of second-generation direct-acting antiviral agents (DAAs). More data are needed to help guide treatment decisions. We investigated the effectiveness and safety of DAAs in patients with genotype 4 infection in routine practice. In this cohort study, HCV genotype 4-infected patients treated with ombitasvir/paritaprevir/ritonavir (OMV/PTVr) + ribavirin (RBV) (n=122) or ledipasvir/sofosbuvir (LDV/SOF) ± RBV (n=130) included in a national database were identified and prospectively followed up. Demographic, clinical and virologic data and serious adverse events (SAEs) were analyzed. Differences between treatment groups mean that data cannot be compared directly. Overall sustained virologic response at Week 12 post treatment (SVR12) was 96.2% with OMV/PTVr+RBV and 95.4% with LDV/SOF±RBV. In cirrhotic patients, SVR12 was 91.2% with OMV/PTVr+RBV and 93.2% with LDV/SOF±RBV. There was no significant difference in SVR12 according to degree of fibrosis in either treatment group (P = .243 and P = .244, respectively). On multivariate analysis, baseline albumin <3.5 g/dL (OMV/PTVr) and bilirubin >2 mg/dL (both cohorts) were significantly associated with failure to achieve SVR (P < .05). Rates of SAEs and SAE-associated discontinuation were 5.7% and 2.5%, respectively, in the OMV/PTVr subcohort and 4.6% and 0.8%, respectively, in the LDV/SOF subcohort. DAA-based regimens returned high rates of SVR12, comparable to limited data from clinical trials, in cirrhotic and non-cirrhotic HCV genotype 4 patients managed in a realworld setting. Safety profiles of both regimens were good and comparable to those reported for other HCV genotypes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 15(2017), 6 vom: 30. Juni, Seite 945-949.e1 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 12.02.2018 Date Revised 31.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cgh.2017.02.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM269309268 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM269309268 | ||
| 003 | DE-627 | ||
| 005 | 20231224224319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2017.02.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0897.xml |
| 035 | |a (DE-627)NLM269309268 | ||
| 035 | |a (NLM)28238958 | ||
| 035 | |a (PII)S1542-3565(17)30200-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crespo, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.02.2018 | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Patients with hepatitis C virus (HCV) genotype 4 infection are poorly represented in clinical trials of second-generation direct-acting antiviral agents (DAAs). More data are needed to help guide treatment decisions. We investigated the effectiveness and safety of DAAs in patients with genotype 4 infection in routine practice. In this cohort study, HCV genotype 4-infected patients treated with ombitasvir/paritaprevir/ritonavir (OMV/PTVr) + ribavirin (RBV) (n=122) or ledipasvir/sofosbuvir (LDV/SOF) ± RBV (n=130) included in a national database were identified and prospectively followed up. Demographic, clinical and virologic data and serious adverse events (SAEs) were analyzed. Differences between treatment groups mean that data cannot be compared directly. Overall sustained virologic response at Week 12 post treatment (SVR12) was 96.2% with OMV/PTVr+RBV and 95.4% with LDV/SOF±RBV. In cirrhotic patients, SVR12 was 91.2% with OMV/PTVr+RBV and 93.2% with LDV/SOF±RBV. There was no significant difference in SVR12 according to degree of fibrosis in either treatment group (P = .243 and P = .244, respectively). On multivariate analysis, baseline albumin <3.5 g/dL (OMV/PTVr) and bilirubin >2 mg/dL (both cohorts) were significantly associated with failure to achieve SVR (P < .05). Rates of SAEs and SAE-associated discontinuation were 5.7% and 2.5%, respectively, in the OMV/PTVr subcohort and 4.6% and 0.8%, respectively, in the LDV/SOF subcohort. DAA-based regimens returned high rates of SVR12, comparable to limited data from clinical trials, in cirrhotic and non-cirrhotic HCV genotype 4 patients managed in a realworld setting. Safety profiles of both regimens were good and comparable to those reported for other HCV genotypes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cirrhosis | |
| 650 | 4 | |a Direct-Acting Antiviral Agents | |
| 650 | 4 | |a Genotype 4 | |
| 650 | 4 | |a Routine Clinical Practice | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Calleja, Jose Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Sacristan, Begoña |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Antorán, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Ampuero, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Conde, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a García-Samaniego, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Gea, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Cabezas, Joaquin |e verfasserin |4 aut | |
| 700 | 1 | |a Lens, Sabela |e verfasserin |4 aut | |
| 700 | 1 | |a Morillas, Rosa Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Salcines, Jose Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Pascasio, Juan Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Turnes, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Sáez-Royuela, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Arenas, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Rincón, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Jorquera, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez Ruano, Juan Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Navascués, Carmen A |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Moya, Adolfo Gallego |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Planas, José Maria |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group |e verfasserin |4 aut | |
| 700 | 1 | |a Montoliu, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Serra, Miguel Angel |e investigator |4 oth | |
| 700 | 1 | |a Andrade, Raul |e investigator |4 oth | |
| 700 | 1 | |a Fernandez, Conrado |e investigator |4 oth | |
| 700 | 1 | |a Fernández Bermejo, Miguel |e investigator |4 oth | |
| 700 | 1 | |a Simon, Miguel Angel |e investigator |4 oth | |
| 700 | 1 | |a Bonet, Lucia |e investigator |4 oth | |
| 700 | 1 | |a de la Vega, Juan |e investigator |4 oth | |
| 700 | 1 | |a Diago, Moises |e investigator |4 oth | |
| 700 | 1 | |a Fernández, José Ramón |e investigator |4 oth | |
| 700 | 1 | |a Sanchez Antolin, Gloria |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g 15(2017), 6 vom: 30. Juni, Seite 945-949.e1 |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2017 |g number:6 |g day:30 |g month:06 |g pages:945-949.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2017.02.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2017 |e 6 |b 30 |c 06 |h 945-949.e1 | ||